GSK cancer drug shows early promise in trials

Published: 12 April 2026. The English Chronicle Desk. The English Chronicle Online.

British pharmaceutical giant GSK has reported encouraging early results from a new cancer treatment. The drug targets ovarian and womb cancers, offering hope to patients with limited options. The findings come as the company accelerates its push into oncology development under new leadership.

The treatment, known as Mocertatug Rezetecan or Mo-Rez, has shown notable effectiveness in early trials. According to the company, tumours shrank or disappeared in 62 percent of ovarian cancer patients. These patients had previously failed to respond to chemotherapy. In endometrial cancer cases, the response rate reached 67 percent, marking a significant breakthrough.

The early-stage trial involved 224 patients across several countries, including the United Kingdom. Researchers monitored both effectiveness and safety throughout the study period. Most patients tolerated the treatment well, with nausea reported as the most common side effect. Importantly, only a small number of participants discontinued treatment due to complications.

These findings were presented at the annual meeting of the Society of Gynecologic Oncology in Puerto Rico. The conference is a key platform for advancing women’s cancer research. Experts from around the world gathered to discuss innovations and emerging therapies.

Hesham Abdullah, GSK’s global head of cancer research, highlighted the urgency of new treatments. He noted that gynaecological cancers remain difficult to treat effectively. Current therapies often fail, leaving patients with limited alternatives. He described the Mo-Rez data as compelling and clinically promising.

The drug belongs to a class known as antibody-drug conjugates, often referred to as ADCs. These treatments combine targeted antibodies with powerful chemotherapy agents. The aim is to deliver drugs directly to cancer cells while limiting damage to healthy tissue. This approach has gained increasing attention in recent years.

GSK acquired Mo-Rez from China’s Hansoh Pharma in late 2023. Since then, the company has moved quickly to test its potential globally. The results, combined with additional data from trials in China, have strengthened confidence in the treatment.

Based on these outcomes, GSK plans to move directly into late-stage trials. The company intends to launch five major clinical studies in the coming months. These trials will include patients in the UK, expanding the drug’s evaluation across diverse populations.

Ovarian and endometrial cancers remain major global health concerns. Endometrial cancer affects around 1.6 million women worldwide. Each year, approximately 417,000 new cases are diagnosed. Ovarian cancer impacts more than 843,000 individuals, with 240,000 new cases annually.

Despite medical advances, survival rates for these cancers remain relatively low. Late diagnosis and resistance to treatment often complicate outcomes. This makes the development of new therapies particularly urgent. Mo-Rez could potentially fill a significant gap in current treatment options.

GSK’s renewed focus on oncology reflects a broader strategic shift. The company had previously stepped back from cancer research. In 2015, it sold its oncology portfolio to Novartis. That deal allowed GSK to strengthen its vaccines business at the time.

However, the company has since re-entered the oncology field with renewed ambition. Under former chief executive Emma Walmsley, GSK began rebuilding its cancer pipeline. Today, it has four approved cancer medicines and thirteen in clinical development.

The company’s oncology division has grown rapidly in recent years. Sales in this segment reached nearly £2 billion last year. This marked a 43 percent increase compared to 2024. One of its key products, the endometrial cancer drug Jemperli, saw sales rise by 89 percent.

Now, under the leadership of Luke Miels, GSK aims to accelerate innovation further. Miels, who took over in January, has emphasised what he calls “scientific courage.” He has already announced several strategic deals since assuming the role.

Miels brings extensive experience from his previous roles at AstraZeneca, Roche, and Sanofi-Aventis. His leadership style focuses on speed, agility, and innovation in drug development. Colleagues describe a renewed sense of urgency across the organisation.

Abdullah, who worked with Miels at AstraZeneca, praised this approach. He said the company is embracing faster decision-making and bold scientific thinking. This shift is already visible in the pace of ongoing research programmes.

The competitive landscape in pharmaceuticals remains intense. AstraZeneca has recently outperformed GSK in commercial terms. Last year, its revenue exceeded GSK’s by more than £10 billion. It also gained global recognition for its Covid-19 vaccine developed with Oxford University.

Despite this, GSK continues to build strengths in key areas. The company has received praise for its work on antimicrobial resistance. It remains one of only three major pharmaceutical firms investing in this field. This commitment highlights its broader focus on global health challenges.

Mo-Rez is expected to become a major asset within GSK’s pipeline. Analysts believe it could achieve annual sales exceeding £2 billion. This would make it a blockbuster drug, supporting GSK’s long-term growth targets. The company aims to reach £40 billion in annual sales by 2031.

Experts caution that early-stage results must be confirmed in larger trials. However, the current data has generated cautious optimism. If successful, Mo-Rez could transform treatment options for thousands of patients worldwide.

For patients facing limited choices, these developments bring renewed hope. Advances in targeted therapies continue to reshape cancer care. While challenges remain, progress like this signals a promising future.

As GSK prepares for the next phase of trials, attention will remain focused on outcomes. The coming months will be critical in determining the drug’s long-term potential. For now, the early results represent an important step forward in cancer research.

Related News:

UK Launches World-First Gonorrhoea Vaccine Amid Record Infection Surge AI Tools Used by English Councils Found to Downplay Women’s Health Issues, Raising Concerns Over Gender Bias in Care Breakthrough Clinical Trial Lets 12-Year-Old Boy with Rare Skin Disorder Play Football Hot Tea and Coffee Found to Contain Highest Levels of Microplastics in Popular Drinks Expanded Access to Health Diagnostics in England Now Available Beyond Standard Hours Shocking Rise in Children’s Exposure to Violent Online Pornography Raises Alarm Ed Davey Urges UK to Attract US Cancer Scientists Amid Funding Cuts Under Trump Omeprazole Alert: NHS Issues Guidance on Safe Use for Heartburn and Indigestion GPs in England Warn of Overload as Nationwide Online Appointment System Approaches Eligibility Confusion Over COVID Vaccination Leaves Pharmacies Struggling Across the UK Majority of UK Men Would Opt for Prostate Cancer Screening, Survey Finds Scientists Announce First Potentially Accurate Blood Test for Chronic Fatigue Syndrome NHS May Pay 25% More for Medicines Amid US Drug Talks Survey Shows Most GPs Rushing Appointments Genetic Tests May Predict Return of Blood Cancer UK Woman Becomes Longest Survivor of Heart-Lung Transplant Thousands in the UK sue Johnson & Johnson over alleged talcum powder, linked to cancer ‘Game-Changing’ HIV Prevention Jab Set for NHS Approval Breath test could ‘revolutionise’ pancreatic cancer treatment How Bringing Forests Into Preschools Boosts Children’s Health Experts Urge Legal Right to Timely Cancer Care Patients to Test Health at Home to Ease NHS Winter Pressure North Sea oil workers must lose weight or face job loss No link found between paracetamol in pregnancy and autism UK launches major AI drive to fight deadly superbugs Coffins Now Too Large to Cremate Amid Rising Obesity Crisis Thinktank Urges Smaller Hospitals to End NHS ‘Permacrisis’ NHS paediatric leave parents waiting months for answers Robo-Vaccination Could Transform Fight Against Bovine TB Cancer Death Rate in Britain Falls by Nearly a Third UK Biobank Health Data Leaks Raise Privacy Concerns Meningitis Cases in Kent Outbreak Rise to 27 UK to Expand Prostate Cancer Trials for Black Men NHS Approves Landmark Ovarian Cancer Drug Concerns Mount Over Accuracy of At-Home Health Tests as Study Calls for Stricter Regulation The Ketamine Crisis in the UK is a Silent Epidemic Leaving Users with Lifelong Pain British Pilot Joins Crew Training for Year-Long Mars Simulation Mission Jaguar Land Rover Extends Production Halt Following Cyber-Attack Systemic Racism in Maternity Care Continues to Endanger Black Women in England, MPs Warn One in Three GPs in England Do Not Work in NHS, Raising Concerns Over Access to Care Persistent Offenders Owe Over £700m in Ulez Fines as TfL Cracks Down on Evasion Questions Remain as Rugby Legend Lewis Moody Faces Motor Neurone Disease Diagnosis Reform UK candidate fined £19,000 after using AI-generated cases to challenge election UK Campaigners Launch Bill to Grant Legal Rights to Nature M&S and Morrisons Lead Christmas Supermarket Taste Test New Prostate Cancer Drug Set to Halve Death Risk in England Hospice Cuts Raise Alarm Across England Amid Funding Crisis UK Bans Fake Numbers: Scammers Lose Their Trick Shouting Works Best to Deter Gulls, UK Study Finds Reeves rejects £1bn plea for NHS redundancy payouts Northern Lights may illuminate UK skies this week New AI tool could cut wasted efforts in organ transplants Stroke Patient Mistaken for Drunk, Care Delayed ‘Traumatic Wait’: Northern Ireland Women Face Breast Cancer Delays Five-Year-Old Dies After Rare Tonsil Surgery Complication Fibromyalgia Patients Struggle as NHS Fails to Provide Care More Patients Now Contacting GPs Online, Data Shows UK Enforces Junk Food Ad Ban Before 9pm Patients Collapsing in NHS Corridors, Watchdog Warns Google Removes Some AI Health Summaries Over Safety Concerns Government Abandons Mandatory Digital ID for UK Workers Streeting moves on doctor pay to end strike dispute Autistic Girls Often Missed in Childhood Diagnoses, Study Finds UK reports baby formula toxin poisoning cases across the country Placenta Accreta Warning as Hunt Urges Action Facial Recognition Error Leads to Wrongful Arrest in Milton Keynes ‘Drinking from a Fetid Pond’: Superbug Genes in Lough Neagh Palantir Boss Defends NHS Deal Amid Government Break Clause Unions Raise Concerns Over Doctors’ Pay Dispute Private Profits From NHS Contracts Spark Urgent National Debate New AI Tool To Target Obesity Risk And Transform NHS Care WHO approves first malaria drug for babies NHS Drug Deal Faces Legal Threat Over US Trade Agreement Record Spending Highlights Growing Crisis In National Health Service Stolen Mobiles Could Soon Become Useless Bricks Clean Air Initiatives Spark Major Fall in London Hospital Admissions UK Ministers Lobby Trump Over Under-16s Social Media Ban NHS Urges Investigation For Irregular Periods UK Schools Struggle as Classrooms Top 40C London Tube Heat Reaches Dangerous Levels